When the industry lost faith in RNAi, Alnylam launched "Alnylam 5x15," a public five-year goal to advance five drugs into the clinic. While it took years to register externally, this bold commitment immediately became a powerful internal rallying cry, injecting hope and focus into the team during a demoralizing period.
Related Insights
People are more motivated by fighting a negative societal trend than by hitting financial targets. Framing your company's work as a "resistance" movement—like fighting loneliness in a digital world—creates a powerful, unifying rally cry for your team.
To secure buy-in for its risky "Platform 2," Zipline built a rough prototype and held a "conviction milestone" event for the whole company. Witnessing the tangible demo converted even the most ardent skeptics on the leadership team, aligning everyone to bet the company's future on the new product.
Over 20 years, Alnylam raised $7.5 billion. Remarkably, this was evenly split between equity financing from capital markets and non-dilutive funding from pharmaceutical partnerships. This balanced strategy was essential for financing a long, capital-intensive R&D journey while managing shareholder dilution.
Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.
During a stock downturn, Rhythm's CFO showed his team historical charts of successful biotech firms like Vertex and Regeneron that also endured long periods of low valuation. This tangible proof of long-term potential in a volatile industry served as a powerful tool to maintain employee morale and focus.
Facing industry-wide skepticism in 2010, Alnylam implemented a highly disciplined R&D strategy. They focused exclusively on targets that met strict criteria: liver expression (where delivery worked), human genetic validation (to de-risk biology), and an early biomarker. This strategic focus was key to their survival and success.
Post-IPO, credibility is a biotech's most valuable asset. Leaders should "under-promise and over-perform" by avoiding specific quarterly guidance for clinical milestones. Instead, use broader windows like "first half of the year" to build in flexibility, as clinical trials rarely run on a perfect schedule.
The industry over-celebrates financial winners. Equal praise should be given to leaders who, despite poor financial outcomes, successfully pioneer new scientific ground or persevere to get a drug approved for a high unmet need. Their work provides crucial groundwork for future successes.
During a dismal post-tech-bubble market, Alnylam secured crucial early funding from pharmaceutical giants. These partners saw the long-term potential of RNAi and were willing to invest when public markets were risk-averse, highlighting pharma's role as a source of patient, visionary capital for platform technologies.
A pivotal moment for Alnylam came when competitor Surna Therapeutics was acquired by Merck for $1.1B. This external validation of the entire RNAi space significantly strengthened investor excitement about Alnylam, making it easier for them to raise capital and secure large partnerships. A rival's success can lift all boats.